JP2005523316A5 - - Google Patents

Download PDF

Info

Publication number
JP2005523316A5
JP2005523316A5 JP2003585725A JP2003585725A JP2005523316A5 JP 2005523316 A5 JP2005523316 A5 JP 2005523316A5 JP 2003585725 A JP2003585725 A JP 2003585725A JP 2003585725 A JP2003585725 A JP 2003585725A JP 2005523316 A5 JP2005523316 A5 JP 2005523316A5
Authority
JP
Japan
Prior art keywords
composition
patient eye
product
effective amount
intraocular pressure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003585725A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005523316A (ja
Filing date
Publication date
Priority claimed from US10/126,790 external-priority patent/US7030149B2/en
Application filed filed Critical
Publication of JP2005523316A publication Critical patent/JP2005523316A/ja
Publication of JP2005523316A5 publication Critical patent/JP2005523316A5/ja
Pending legal-status Critical Current

Links

JP2003585725A 2002-04-19 2003-04-09 眼科局所用のブリモニジンとチモロールとの組み合わせ Pending JP2005523316A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/126,790 US7030149B2 (en) 2002-04-19 2002-04-19 Combination of brimonidine timolol for topical ophthalmic use
PCT/US2003/010885 WO2003088973A1 (en) 2002-04-19 2003-04-09 Combination of brimonidine and timolol for topical ophthalmic use

Publications (2)

Publication Number Publication Date
JP2005523316A JP2005523316A (ja) 2005-08-04
JP2005523316A5 true JP2005523316A5 (enExample) 2006-01-05

Family

ID=29215107

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003585725A Pending JP2005523316A (ja) 2002-04-19 2003-04-09 眼科局所用のブリモニジンとチモロールとの組み合わせ

Country Status (17)

Country Link
US (16) US7030149B2 (enExample)
EP (2) EP2241319A1 (enExample)
JP (1) JP2005523316A (enExample)
KR (1) KR100723189B1 (enExample)
CN (2) CN101664414A (enExample)
BR (1) BR0302584A (enExample)
CA (1) CA2440764C (enExample)
CY (1) CY1114048T1 (enExample)
DK (1) DK1496912T3 (enExample)
ES (1) ES2399045T3 (enExample)
MX (2) MXPA03008401A (enExample)
NO (1) NO326579B1 (enExample)
NZ (1) NZ528945A (enExample)
PT (1) PT1496912E (enExample)
SI (1) SI1496912T1 (enExample)
TW (1) TWI351959B (enExample)
WO (1) WO2003088973A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026924A1 (en) * 2000-07-14 2005-02-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
CN100413503C (zh) * 2005-01-07 2008-08-27 冷文 一种复方眼药组合物
US7534795B2 (en) * 2005-10-25 2009-05-19 Allergan, Inc. Compounds and their use related to compositions for treating disease
US20070238732A1 (en) * 2006-04-10 2007-10-11 Allergan, Inc. Brimonidine and timolol compositions
US20080051406A1 (en) * 2006-08-25 2008-02-28 Richard Graham Brimonidine and timolol compositions
WO2008024846A2 (en) * 2006-08-25 2008-02-28 Allergan, Inc. Brimonidine and timolol compositions
MX2007010025A (es) * 2007-08-17 2009-02-25 Arturo Jimenez Bayardo Composición farmacéutica para tratamiento de hipertensión ocular.
MX2007011165A (es) * 2007-09-12 2009-03-11 Arturo Jimenez Bayardo Composición farmacéutica estable de timolol, dorzolamida y brimonidina.
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US20100028266A1 (en) 2008-08-01 2010-02-04 Alpha Synergy Development. Inc. Composition and methods for treating allergic response
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
JP5218167B2 (ja) 2009-03-11 2013-06-26 日立電線株式会社 コネクタ
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US20100298335A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
US8317973B2 (en) * 2009-11-11 2012-11-27 Kemira Chemical, Inc. Polyester surfactants for deinking
CA2782872A1 (en) * 2009-12-17 2011-06-23 Alpha Synergy Development, Inc. Compositions and methods for ophthalmic delivery of nasal decongestants
BR112012017319A2 (pt) * 2009-12-22 2016-04-19 Allergan Inc composições e métodos para abaixar a pressão intraocular
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
PT2598119T (pt) 2010-07-29 2018-12-17 Allergan Inc Soluções de brimonidina e timolol isentas de conservantes
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
CN104114154A (zh) * 2011-12-16 2014-10-22 阿勒根公司 包含聚乙烯基己内酰胺-聚乙酸乙烯酯-聚乙二醇接枝共聚物(Soluplus)的眼用组合物
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
US20180078500A1 (en) * 2015-03-19 2018-03-22 Allergan, Inc. Fixed dose combination of brimonidine and timolol
CA3033507A1 (en) 2016-08-12 2018-02-15 Silk Technologies, Ltd. Silk-derived protein for treating inflammation
WO2018033854A1 (en) 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
EP3576770A1 (en) * 2017-02-01 2019-12-11 Shire Human Genetic Therapies, Inc. Compounds and compositions for the treatment of ophthalmic disorders
MX2019014748A (es) * 2017-06-08 2020-08-03 Eye Therapies Llc Combinaciones de brimonidina de dosis baja y usos de las mismas.
US20200108064A1 (en) * 2017-06-08 2020-04-09 Eye Therapies, Llc Low-dose brimonidine combinations and uses thereof
CN111132640B (zh) * 2017-09-25 2023-01-10 佛罗里达大学研究基金会股份有限公司 从含亲水药物的滴眼剂中除去防腐剂
US20190134051A1 (en) * 2017-11-06 2019-05-09 Rheostasis, Llc Composition for treating ocular disorders such as macular degeneration, retinopathy and glaucoma
AU2019246035B2 (en) * 2018-03-28 2024-07-18 Novaliq Gmbh Pharmaceutical composition comprising timolol
US11871308B2 (en) * 2019-07-29 2024-01-09 TapText llc System and method for link-initiated dynamic-mode communications
US20220411482A1 (en) 2019-11-15 2022-12-29 Silk Technologies, Ltd. Stable formulations of silk-derived protein
IL293976A (en) 2019-12-19 2022-08-01 Tearclear Corp Preservative removal from eye drops
CN120617269A (zh) * 2025-06-16 2025-09-12 鲁南贝特制药有限公司 一种溴莫尼定噻吗洛尔滴眼液及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4029792A (en) 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US4195085A (en) * 1975-09-26 1980-03-25 Merck & Co., Inc. Compositions and methods for treating glaucoma by the topical administration of t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy-2-phopanol hydrogen maleate
FR2588189B1 (fr) * 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US4910225A (en) * 1988-01-27 1990-03-20 Senju Pharmaceutical Co., Ltd. Locally administrable therapeutic composition for inflammatory disease
CA1334168C (en) 1988-04-26 1995-01-31 Louis M. De Santis Antiglaucoma compositions containing combinations of .alpha.-2 agonists and .beta. blockers
CA2003198C (en) * 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5021410A (en) * 1989-05-22 1991-06-04 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5215991A (en) 1990-01-26 1993-06-01 Allergan, Inc. Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
DE4201079C3 (de) 1992-01-17 1997-09-11 Gramer Eugen Kombinationspräparate zur Augeninnendrucksenkung
US5290781A (en) * 1993-01-05 1994-03-01 Iolab Corporation Ketaneserinol as an agent to reduce intraocular pressure
TW354762B (en) * 1993-02-23 1999-03-21 Otsuka Pharma Co Ltd Agent for prophylaxis or treatment of cataract
DE69425334T2 (de) 1993-12-17 2001-02-08 The Procter & Gamble Company, Cincinnati 6-(2-imidazolinylamino) chinoxalin-verbindungen als alpha-2-adrenorezeptoragonisten
US5440505A (en) * 1994-01-21 1995-08-08 Intel Corporation Method and circuitry for storing discrete amounts of charge in a single memory element
SE9401109D0 (sv) * 1994-03-31 1994-03-31 Leiras Oy Opthalmic composition II
US5564596A (en) 1994-05-05 1996-10-15 Allergan, Inc. Multiple fluid dispensing device for low surface tension formulations
US6294563B1 (en) * 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5856329A (en) * 1995-06-28 1999-01-05 Allergan Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
CA2237898A1 (en) 1995-11-17 1997-05-29 Louis Desantis Jr. Combination therapy for treating glaucoma
US6441047B2 (en) * 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US6159458A (en) * 1997-11-04 2000-12-12 Insite Vision Sustained release ophthalmic compositions containing water soluble medicaments
US6174524B1 (en) * 1999-03-26 2001-01-16 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
WO1999051273A1 (en) * 1998-04-07 1999-10-14 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
US6440964B1 (en) * 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
US6740664B2 (en) * 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
US6146622A (en) 1998-10-27 2000-11-14 Alcon Laboratories, Inc. Use of certain anionic amino acid based surfactants to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
US6242442B1 (en) * 1998-12-17 2001-06-05 Alcon Laboratories, Inc. Brinzolamide and brimonidine for treating ocular conditions
US6410045B1 (en) * 1999-02-22 2002-06-25 Clyde Lewis Schultz Drug delivery system for antiglaucomatous medication
EP1299123A2 (en) * 2000-07-13 2003-04-09 Pharmacia Corporation Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
CA2416169C (en) * 2000-07-14 2008-09-23 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
EP1365811A2 (en) * 2000-07-14 2003-12-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
TWI292914B (enExample) * 2002-01-17 2008-01-21 Macronix Int Co Ltd
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US7642258B2 (en) 2002-04-19 2010-01-05 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
KR100521364B1 (ko) * 2002-11-18 2005-10-12 삼성전자주식회사 플레쉬 메모리 셀들의 프로그램 오판을 방지하고 균일한문턱 전압 산포를 가질 수 있는 플레쉬 메모리 장치 및 그프로그램 검증 방법

Similar Documents

Publication Publication Date Title
US20120004158A1 (en) Quaternised Ammonium Cyclodextrin Compounds
AU2011274245B2 (en) Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease
WO2019216381A1 (ja) 眼科組成物
JP2019507758A5 (enExample)
JP2021102626A5 (enExample)
JP7787129B2 (ja) 眼科組成物
WO2017042404A1 (es) Composición farmacéutica de tramadol para uso oftálmico
JP7348347B2 (ja) 眼科組成物
AU2016233125A1 (en) Fixed dose combination of bromonidine and timolol
JP2006232822A (ja) プラノプロフェン含有組成物
KR20190071674A (ko) 안과용 제제 및 안과용 약
JP2019006776A (ja) 水溶性高分子を含む点眼剤
JP4718160B2 (ja) 眼科用組成物
WO2023024126A1 (zh) 一种含伏立康唑的眼用凝胶剂及其制备方法与应用
CN115634226B (zh) 一种采用长春西汀治疗近视的方法
ES2974884T3 (es) Composición de colirio para reducir la presión intraocular
JP2004536847A5 (enExample)
TWI896143B (zh) 一種有效延緩及治療近視的藥物組合物
KR20100032018A (ko) 항히스타민제를 포함하는 점안용 조성물
CA3292554A1 (en) Pharmaceutical composition for effectively delaying and treating myopia
EP3681473A1 (en) Topical formulations of chloroprocaine
CN108348457A (zh) 无菌水性眼用溶液的治疗用途
Goldberg Comparison of tropical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J. Glaucoma 2001; 10: 414-22
CA2470866A1 (en) Uses of dorzolamide to improve night vision
HK40005358A (en) Eye-drop composition for lowering intraocular pressure